[1]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价[J].西部中医药,2013,26(12):1-4.
　REN Fang,XU Houqian.Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):1-4.
点击复制

黄芪注射液治疗糖尿病肾病随机对照试验报告质量评价
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年12期
页码:
1-4
栏目:
出版日期:
2013-12-15

文章信息/Info

Title:
Quality Evaluation of the Report for Randomized Controlled Trials of HuangQi Injection in Treating Diabetic Nephropathy
文章编号:
1004-6852(2013)12-0001-04
作者:
任芳1，2，徐厚谦1△
1 甘肃中医学院，甘肃 兰州 730000； 2 金昌市第一人民医院内科
Author(s):
REN Fang1, 2, XU Houqian1△
1 Gansu University of Traditional Chinese Medicine, Lanzhou 730000, China; 2 Department of Internal Medicine in Jinchang Municipal the First People′s Hospital
关键词:
黄芪注射液; 糖尿病肾病; 随机对照试验; CONSORT声明; 报告质量评价
Keywords:
HuangQi injection;  diabetic nephropathy;  randomized controlled trial;  CONSORT standard; quality evaluation of the report
分类号:
R587.1
文献标志码:
A
摘要:
目的：应用CONSORT标准评价Jadad评分≥3分的有关黄芪注射液治疗糖尿病肾病的RCT报告质量。方法：按照Cochrane协作网制定的检索策略检索出2013年1月以前的所有有关黄芪注射液治疗糖尿病肾病的随机和半随机对照临床试验。应用CONSORT声明和一些中医药评价指标对Jadad评分≥3分的RCT文献的报告质量进行综合评价。数据提取和文献方法学质量评价由2名评价人员独立完成，如有争议通过讨论或由主要研究者解决。结果：共检出480篇文献，只有16篇RCT符合纳入标准。在纳入的16篇RCT中，含诊断标准的有16篇，占100.0%；说明详细用药方案及疗程的有14篇，占87.5%；正确地说明随机分配方法的有11篇，占68.75%；说明统计学方法的有15篇，占93.75%；描述对象纳入期间的有12篇，占75.0%；描述各组基线资料的有14篇，占87.5%；提及退出/失访例数的有5篇，占31.25%；提及不良反应的有9篇，占56.25%；描述中医证型的只有1篇，占6.25%。没有1篇文献提及样本含量的估计、分配方案的隐藏和实施、受试对象流程图，意向性治疗分析和终点指标观察。结论：大部分RCT的方法学及结果部分报告不够详细，建议尽量按照CONSORT标准来报告RCT以提高RCT的报告质量和真实性。
Abstract:
Objective: To evaluate the quality of randomized controlled trial (RCT) report about HuangQi injection in treating diabetic nephropathy(DN) with Jadad scales≥three points by CONSORT standard. Method: All the papers of randomized and semi-randomized controlled clinical trials about HuangQi injection in treating DN were searched before January, 2013, quality of RCT report with Jadad scales≥three points was assessed comprehensively by CONSORT statement and some TCM indexes. Data extraction and quality evaluation of literature methodology were performed by two judges independently. If there was the dispute, it should be solved through discussion or main investigators. Result: Altogether 480 articles were detected, and only 16 pieces met the standard. Among 16 included articles, there were 16 articles with diagnostic criteria, which accounted for 100.0%; 14 ones with detailed medication plan and the course of the treatment, which reached 87.5%; 11 ones with right demonstration of randomized distribution method, and 68.75%; 15 with the presentation of statistical method, and 93.75%; 12 pieces with the description of the included objects and 75.0%; 14 ones describing baseline information in different groups and 87.5%; five pieces referring to the number of the cases quit or dropped, and 31.25%; nine articles talking about adverse reactions and 56.25%; only one piece discussing TCM patterns and 6.25%. There was no article mentioning the estimate of samples contents, the hide and implementation of distribution plan, flowchart of the objects, intention-to-treat analysis and observation of endpoint indexes. Conclusion: Since methodology and results for most of the RCT are not reported in detail, we suggest that RCT should be reported according to CONSORT standard to improve the quality and the authenticity of RCT.

相似文献/References:

[1]林晓芬,黄燕璇.益肾汤联合厄贝沙坦及胰激肽原酶治疗早期糖尿病肾病的疗效观察[J].西部中医药,2013,26(07):68.
　LIN Xiaofen,HUANG Yanxuan.Clinical Observation on YiShenTang Combined with Irbesartan and Pancreatic Kininogenase in the Treatment for Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):68.
[2]王学琦,李丰华,张荣华,等.温肾汤治疗早期糖尿病肾病80例[J].西部中医药,2013,26(09):62.
　WANG Xueqi,LI Fenghua,ZHANG Ronghua,et al.WenShenTang for 80 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):62.
[3]丁夏楠,许筠△,苏建平,等.益肾逐瘀方治疗糖尿病肾病蛋白尿37例[J].西部中医药,2014,27(04):96.
　DING Xianan,XU Jun,SU Jianping,et al.Treatment for Proteinuria of 37 Patients with Diabetic Nephropathy by Kidney-invigorating Stagnation-dispelling Prescription[J].Western Journal of Traditional Chinese Medicine,2014,27(12):96.
[4]肖远莉.循证护理的优效性及影响因素分析———来自终末期糖尿病肾病患者血液透析的证据[J].西部中医药,2014,27(08):127.
[5]王晓怀,寇嘉宁,潘文,等.黄芪注射液治疗脑梗死的Meta分析[J].西部中医药,2014,27(10):67.
[6]刘涛.缬沙坦联合复方丹参滴丸对早期2型糖尿病肾病患者尿微量白蛋白的影响[J].西部中医药,2015,28(05):106.
[7]杨国军.黄芪注射液对2型糖尿病患者血管功能及微循环状态的影响[J].西部中医药,2015,28(05):109.
[8]连琯,史晓伟.当归补血汤合金水宝治疗早期糖尿病肾病16例临床观察[J].西部中医药,2013,26(06):68.
　LIAN Guan,SHI Xiaowei.Clinical Observation on DangGui BuXueTang and JinShuiBao in Treating 16 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):68.
[9]朱苗蕊,指导：金智生.糖脂平治疗早期糖尿病肾病60例疗效观察*[J].西部中医药,2013,26(03):74.
　ZHU Miaorui,Director: JIN Zhisheng.Clinical Observation on TangZhiPing in Treating 60 Cases of Early Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):74.
[10]马天寿.血塞通联合西药治疗糖尿病肾病80例[J].西部中医药,2013,26(08):96.
　MA Tianshou.XueSaiTong Injection and Western Medicine in Treating 80 Cases of Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2013,26(12):96.
[11]任芳,徐厚谦△.黄芪注射液治疗糖尿病肾病有效性及安全性的系统评价[J].西部中医药,2014,27(01):77.
　REN Fang,XU Houqian.Systematic Review of the Effectiveness and Safety of HuangQi Injection in Treating Diabetic Nephropathy[J].Western Journal of Traditional Chinese Medicine,2014,27(12):77.

备注/Memo

备注/Memo:
收稿日期：2013-06-17。作者简介：任芳(1982—)，女，硕士研究生，主治医师。研究方向：类风湿性关节炎疾病的中西医结合治疗。△通讯作者：徐厚谦(1960—)，男，硕士研究生导师，教授，副主任医师。研究方向：高校教学和中医药防治心血管疾病。
更新日期/Last Update: 2013-12-15